Novartis/$NVS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Ticker
$NVS
Sector
Primary listing
NYSE
Employees
75,267
Headquarters
Basel, Switzerland
Website
Novartis Metrics
BasicAdvanced
$311B
22.75
$7.15
0.46
$2.60
1.60%
Price and volume
Market cap
$311B
Beta
0.46
52-week high
$167.86
52-week low
$97.72
Average daily volume
2.2M
Dividend rate
$2.60
Financial strength
Current ratio
1.117
Quick ratio
0.82
Long term debt to equity
63.572
Total debt to equity
76.171
Dividend payout ratio (TTM)
55.91%
Interest coverage (TTM)
16.61%
Profitability
EBITDA (TTM)
23,473
Gross margin (TTM)
75.97%
Net profit margin (TTM)
24.67%
Operating margin (TTM)
33.53%
Effective tax rate (TTM)
14.59%
Revenue per employee (TTM)
$750,000
Management effectiveness
Return on assets (TTM)
11.14%
Return on equity (TTM)
30.81%
Valuation
Price to earnings (TTM)
22.751
Price to revenue (TTM)
5.565
Price to book
5.23
Price to tangible book (TTM)
-27.27
Price to free cash flow (TTM)
20.47
Free cash flow yield (TTM)
4.89%
Free cash flow per share (TTM)
7.947
Dividend yield (TTM)
1.60%
Forward dividend yield
1.60%
Growth
Revenue change (TTM)
9.57%
Earnings per share change (TTM)
21.81%
3-year revenue growth (CAGR)
9.25%
10-year revenue growth (CAGR)
1.18%
3-year earnings per share growth (CAGR)
31.11%
10-year earnings per share growth (CAGR)
-0.20%
3-year dividend per share growth (CAGR)
10.48%
10-year dividend per share growth (CAGR)
5.64%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Novartis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $311B as of February 21, 2026.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 22.75 as of February 21, 2026.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of February 21, 2026, the dividend rate is $2.59609 and the yield is 1.6%. Novartis has a payout ratio of 55.91% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment is scheduled for March 16, 2026.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.